Drugs / Sialic Acid Extended Release
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01517880 | May 2012 → Nov 2013 | hereditary inclusion-body myopathy | Ultragenyx Pharmaceutical Inc | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Sialic Acid Extended Release | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01517880 ↗ |
| Known as | SA-ER | “Sialic Acid Extended Release (SA-ER)” NCT01517880 ↗ |
| Action | Restore | “restoring sialylation of muscle by treatment with SA-ER” NCT01517880 ↗ |